{"id":744916,"date":"2014-10-06T11:28:00","date_gmt":"2014-10-06T11:28:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-eur-2-5-billion-debt-offering\/"},"modified":"2023-03-22T00:04:50","modified_gmt":"2023-03-22T04:04:50","slug":"merck-prices-eur-2-5-billion-debt-offering","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-eur-2-5-billion-debt-offering\/","title":{"rendered":"Merck Prices EUR 2.5 Billion Debt Offering"},"content":{"rendered":"<p>\n      Merck &#038; Co., Inc. (the \u201cCompany\u201d) (NYSE:MRK), known as MSD outside of<br \/>\n      the United States and Canada, priced today EUR 2.5 billion public<br \/>\n      offering of three series of Euro-denominated senior unsecured notes<br \/>\n      (collectively, the \u201cNew Notes\u201d). Based on Oct. 3, 2014, closing exchange<br \/>\n      rates the EUR 2.5 billion equates to approximately $3.1 billion. The<br \/>\n      notes include:\n    <\/p>\n<p class=\"bwalignc\">\n      EUR 1.0 billion of 1.125% notes due Oct. 2021<br \/>EUR 1.0 billion of<br \/>\n      1.875% notes due Oct. 2026<br \/>EUR 500 million of 2.500% notes due Oct.<br \/>\n      2034\n    <\/p>\n<p>\n      The Company intends to use all or a substantial portion of the net<br \/>\n      proceeds from the offering of the New Notes to purchase notes and<br \/>\n      debentures that are validly tendered in connection with tender offers<br \/>\n      launched by the Company for certain outstanding notes and debentures<br \/>\n      (collectively, the \u201cOld Notes\u201d). If there are net proceeds remaining<br \/>\n      after the tender offers, the Company intends to redeem in whole or in<br \/>\n      part, its 4.00% Notes due 2015 and 6.00% Senior Notes due 2017. Any<br \/>\n      remaining net proceeds will be used for general corporate purposes,<br \/>\n      including without limitation the repayment of outstanding commercial<br \/>\n      paper borrowings and other indebtedness with upcoming maturities. If the<br \/>\n      net proceeds of the offering for the New Notes are insufficient to pay<br \/>\n      for all of the notes and debentures acquired by the Company in the<br \/>\n      tender offers, the Company will fund any additional amounts from cash on<br \/>\n      hand, commercial paper borrowings or other amounts available to the<br \/>\n      Company. The offering is expected to close on Oct. 15, 2014, subject to<br \/>\n      customary closing conditions. BNP Paribas, Deutsche Bank AG, London<br \/>\n      Branch and J.P. Morgan Securities plc are acting as the active joint<br \/>\n      book-running managers for the offering. Merrill Lynch International and<br \/>\n      The Royal Bank of Scotland plc are acting as the passive joint<br \/>\n      book-running managers for the offering.\n    <\/p>\n<p>\n      The offering of the New Notes is being made pursuant to an effective<br \/>\n      shelf registration statement (including a base prospectus) filed with<br \/>\n      the Securities and Exchange Commission (the \u201cSEC\u201d). The offering may be<br \/>\n      made only by means of a prospectus and related prospectus supplement,<br \/>\n      copies of which may be obtained by calling BNP Paribas at (800) 854-5674<br \/>\n      (toll-free), Deutsche Bank AG, London Branch at (800) 503-4611<br \/>\n      (toll-free) or J.P. Morgan Securities plc at (866) 834-4666 (toll-free)<br \/>\n      or (212) 834-4811 (collect). An electronic copy of the registration<br \/>\n      statement and prospectus supplement, together with the base prospectus,<br \/>\n      is available on the SEC\u2019s website at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50956461&#038;newsitemid=20141006006239&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=1&#038;md5=f7844ceadf097912d72a0ce5c17e751d\" rel=\"nofollow\">www.sec.gov<\/a>.\n    <\/p>\n<p>\n      This press release does not constitute an offer to sell or a<br \/>\n      solicitation of an offer to buy the securities described herein, nor<br \/>\n      shall there be any sale of these securities in any state or jurisdiction<br \/>\n      in which such an offer, solicitation or sale would be unlawful prior to<br \/>\n      registration or qualification under the securities laws of any such<br \/>\n      jurisdiction.\n    <\/p>\n<p>\n      Additionally, this press release shall not constitute an offer to<br \/>\n      purchase or a solicitation of an offer to sell the Company\u2019s Old Notes<br \/>\n      in the tender offers. The tender offers will be made only by and<br \/>\n      pursuant to, and on the terms and subject to, the conditions set forth<br \/>\n      in an offer to purchase. Furthermore, this press release does not<br \/>\n      constitute a notice of redemption or an obligation to issue a notice of<br \/>\n      redemption.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. Such statements may include,<br \/>\n      but are not limited to, Merck\u2019s ability to complete the offering and<br \/>\n      Merck\u2019s expectations for the use of proceeds from the offering. These<br \/>\n      statements are based upon the current beliefs and expectations of<br \/>\n      Merck\u2019s management and are subject to significant risks and<br \/>\n      uncertainties. If underlying assumptions prove inaccurate or risks or<br \/>\n      uncertainties materialize, actual results may differ materially from<br \/>\n      those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the SEC available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50956461&#038;newsitemid=20141006006239&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=2&#038;md5=7b6f20cc26d73ab7e77fa2a671a2ad1f\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20141006006239r1&#038;sid=hq1sc1&#038;distro=nx&#038;lang=en\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck &#038; Co., Inc.<br \/>Media:<br \/>Steven Cragle, 908-423-3461<br \/>Lainie        Keller, 908-236-5036<br \/>Investor:<br \/>Joe Romanelli, 908-423-5185<br \/>Justin        Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck &#038; Co., Inc. (the \u201cCompany\u201d) (NYSE:MRK), known as MSD outside of the United States and Canada, priced today EUR 2.5 billion public offering of three series of Euro-denominated senior unsecured notes (collectively, the \u201cNew Notes\u201d). Based on Oct. 3, 2014, closing exchange rates the EUR 2.5 billion equates to approximately $3.1 billion. The notes include: EUR 1.0 billion of 1.125% notes due Oct. 2021 EUR 1.0 billion of 1.875% notes due Oct. 2026 EUR 500 million of 2.500% notes due Oct. 2034 The Company intends to use all or a substantial portion of the net proceeds from the offering of the New Notes to purchase notes and debentures that are validly tendered in connection with tender offers launched by the Company for certain outstanding notes and debentures (collectively, the \u201cOld Notes\u201d). If there are net proceeds remaining after the tender offers, the Company intends to redeem in whole or in part, its 4.00% Notes due 2015 and 6.00% Senior Notes due 2017. Any remaining net<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,52,64,289],"class_list":["post-744916","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-financial-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Prices EUR 2.5 Billion Debt Offering - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-eur-2-5-billion-debt-offering\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Prices EUR 2.5 Billion Debt Offering - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck &amp; Co., Inc. (the \u201cCompany\u201d) (NYSE:MRK), known as MSD outside of the United States and Canada, priced today EUR 2.5 billion public offering of three series of Euro-denominated senior unsecured notes (collectively, the \u201cNew Notes\u201d). Based on Oct. 3, 2014, closing exchange rates the EUR 2.5 billion equates to approximately $3.1 billion. The notes include: EUR 1.0 billion of 1.125% notes due Oct. 2021 EUR 1.0 billion of 1.875% notes due Oct. 2026 EUR 500 million of 2.500% notes due Oct. 2034 The Company intends to use all or a substantial portion of the net proceeds from the offering of the New Notes to purchase notes and debentures that are validly tendered in connection with tender offers launched by the Company for certain outstanding notes and debentures (collectively, the \u201cOld Notes\u201d). If there are net proceeds remaining after the tender offers, the Company intends to redeem in whole or in part, its 4.00% Notes due 2015 and 6.00% Senior Notes due 2017. Any remaining net\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-eur-2-5-billion-debt-offering\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:50+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20141006006239r1&sid=hq1sc1&distro=nx&lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-prices-eur-2-5-billion-debt-offering\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-prices-eur-2-5-billion-debt-offering\\\/\",\"name\":\"Merck Prices EUR 2.5 Billion Debt Offering - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-prices-eur-2-5-billion-debt-offering\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-prices-eur-2-5-billion-debt-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20141006006239r1&sid=hq1sc1&distro=nx&lang=en\",\"datePublished\":\"2014-10-06T11:28:00+00:00\",\"dateModified\":\"2023-03-22T04:04:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-prices-eur-2-5-billion-debt-offering\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-prices-eur-2-5-billion-debt-offering\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-prices-eur-2-5-billion-debt-offering\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20141006006239r1&sid=hq1sc1&distro=nx&lang=en\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20141006006239r1&sid=hq1sc1&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-prices-eur-2-5-billion-debt-offering\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Prices EUR 2.5 Billion Debt Offering\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Prices EUR 2.5 Billion Debt Offering - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-eur-2-5-billion-debt-offering\/","og_locale":"en_US","og_type":"article","og_title":"Merck Prices EUR 2.5 Billion Debt Offering - Merck.com","og_description":"Merck & Co., Inc. (the \u201cCompany\u201d) (NYSE:MRK), known as MSD outside of the United States and Canada, priced today EUR 2.5 billion public offering of three series of Euro-denominated senior unsecured notes (collectively, the \u201cNew Notes\u201d). Based on Oct. 3, 2014, closing exchange rates the EUR 2.5 billion equates to approximately $3.1 billion. The notes include: EUR 1.0 billion of 1.125% notes due Oct. 2021 EUR 1.0 billion of 1.875% notes due Oct. 2026 EUR 500 million of 2.500% notes due Oct. 2034 The Company intends to use all or a substantial portion of the net proceeds from the offering of the New Notes to purchase notes and debentures that are validly tendered in connection with tender offers launched by the Company for certain outstanding notes and debentures (collectively, the \u201cOld Notes\u201d). If there are net proceeds remaining after the tender offers, the Company intends to redeem in whole or in part, its 4.00% Notes due 2015 and 6.00% Senior Notes due 2017. Any remaining net","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-eur-2-5-billion-debt-offering\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:50+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20141006006239r1&sid=hq1sc1&distro=nx&lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-eur-2-5-billion-debt-offering\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-eur-2-5-billion-debt-offering\/","name":"Merck Prices EUR 2.5 Billion Debt Offering - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-eur-2-5-billion-debt-offering\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-eur-2-5-billion-debt-offering\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20141006006239r1&sid=hq1sc1&distro=nx&lang=en","datePublished":"2014-10-06T11:28:00+00:00","dateModified":"2023-03-22T04:04:50+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-eur-2-5-billion-debt-offering\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-eur-2-5-billion-debt-offering\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-eur-2-5-billion-debt-offering\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20141006006239r1&sid=hq1sc1&distro=nx&lang=en","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20141006006239r1&sid=hq1sc1&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-eur-2-5-billion-debt-offering\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Prices EUR 2.5 Billion Debt Offering"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"b7e7e01b-f3e9-431f-978e-15f434b34f12","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744916","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744916\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=744916"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=744916"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}